Uvea Melanomlarında Uygulanan Tedavi Seçeneklerinin Yaşam ve Görme İşlevi Üzerindeki Etkilerinin Değerlendirilmesi
xmlui.mirage2.itemSummaryView.MetaDataShow full item record
Uveal melanoma is the most common primary malignant intraocular tumor in adults, with a 10-year cumulative metastatic rate of 34%. The most common site of metastasis is the liver (95%). Uveal melanomas can be treated by various forms and combinations of radiotherapy (plaque, proton beam or stereotactic radiotherapy), enuclation and transpupillary thermotherapy, which need to be tailored to the tumour size and location. The aim of the study was to determine the relationship between the first ? line treatment and metastasis. Patients were followed up for more than an avarege of 5 years. A retrospective analysis of the medical records of 502 eyes of 502 patients who underwent enucleation (194 patients), plaque (61 patients), cyberknife® (155 patients) or stereotactic radiotherapy (19 patients), and transpupillary thermotherapy (73 patients) for uveal melanoma . Demographic and clinical information included age at time time of presentation, gender, laterality, visual acuity at diagnosis, associated serous retinal detachment and vıtreous hemorrhage, need for additional treatment, the protection of the eye tumor, metastasis, tumor-related mortality, treatment-related complications. The evaluation found that the group treated with stereotactic radiotherapy most metastasis, metastasis at least was in the group treated with transpupillary thermotherapy (p=0.002). In terms of conservation of the eye, there is not a statistically significant difference in treatment options. Transpupillary thermotherapy need for re-treatment than the others. (p=0.001).